Beijing Konruns Pharmaceutical Co.,Ltd. (SHA:603590)
China flag China · Delayed Price · Currency is CNY
25.59
-0.29 (-1.12%)
Nov 6, 2026, 10:24 AM CST

SHA:603590 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
862.24914.24824.43917.75851.05693.03
Other Revenue
0.880.880.972.2615.68116.76
863.12915.12825.4920.01866.73809.78
Revenue Growth
-0.94%10.87%-10.28%6.15%7.03%0.14%
Cost of Revenue
90.0292.2586.26101.05126.65105.76
Gross Profit
773.1822.87739.14818.96740.07704.02
Selling, General & Admin
527.94567.52553.76583.28525.88479.34
Research & Development
84.3551.8654.9494.9186.78102.27
Other Operating Expenses
10.589.046.755.646.048.69
Operating Expenses
623.54639.7620.37689.42620.56591.51
Operating Income
149.56183.17118.77129.54119.51112.51
Interest Expense
-2.13-7.53-6.16-2.78-0.86-1.41
Interest & Investment Income
23.1326.6830.9819.3318.5224.57
Currency Exchange Gain (Loss)
-3.84-3.84-1.290.50.260.31
Other Non Operating Income (Expenses)
2.86-3.31-1.56-1.7-0.361.58
EBT Excluding Unusual Items
169.58195.16140.74144.9137.06137.57
Impairment of Goodwill
---97.64---
Gain (Loss) on Sale of Investments
6.764.18-0.49-12.78-7.6535.64
Gain (Loss) on Sale of Assets
-0.65-0.52-0.03-0.13-0.010
Asset Writedown
-0.02-0.02-7.77--4.06-
Other Unusual Items
-10.19-9.114.05-9.2614.9815.64
Pretax Income
165.48189.6938.86122.73140.32188.86
Income Tax Expense
26.1720.2617.33-64.8416.4221.42
Earnings From Continuing Operations
139.31169.4221.53187.57123.89167.44
Minority Interest in Earnings
-1.43-3.4620.69-37.12-22.4-19.46
Net Income
137.89165.9742.22150.45101.49147.99
Net Income to Common
137.89165.9742.22150.45101.49147.99
Net Income Growth
141.39%293.13%-71.94%48.24%-31.42%-19.29%
Shares Outstanding (Basic)
157158156157156157
Shares Outstanding (Diluted)
160160156157156157
Shares Change
1.85%2.06%-0.23%0.37%-0.82%-1.26%
EPS (Basic)
0.881.050.270.960.650.94
EPS (Diluted)
0.861.040.270.960.650.94
EPS Growth
137.01%285.19%-71.88%47.69%-30.85%-18.26%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1.6162.2368.2298.4423.38-108.43
Free Cash Flow Per Share
-0.010.390.440.630.15-0.69
Dividend Per Share
0.3500.3500.6000.3000.2000.300
Dividend Growth
-41.67%-41.67%100.00%50.00%-33.33%-14.29%
Gross Margin
89.57%89.92%89.55%89.02%85.39%86.94%
Operating Margin
17.33%20.02%14.39%14.08%13.79%13.89%
Profit Margin
15.97%18.14%5.12%16.35%11.71%18.27%
Free Cash Flow Margin
-0.19%6.80%8.27%10.70%2.70%-13.39%
EBITDA
177.75212.67150.01165.35151.54144.29
EBITDA Margin
20.59%23.24%18.17%17.97%17.48%17.82%
D&A For EBITDA
28.1929.531.2435.832.0331.78
EBIT
149.56183.17118.77129.54119.51112.51
EBIT Margin
17.33%20.02%14.39%14.08%13.79%13.89%
Effective Tax Rate
15.81%10.68%44.60%-11.70%11.34%
Revenue as Reported
222.9915.12825.4920.01866.73809.78
Advertising Expenses
----32.55350.29